Breaking Down the PAH Cost Burden

EP: 1.Evolving Guidelines for PAH Treatment

EP: 2.New Therapeutic Frontiers in PAH

EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

Now Viewing

EP: 5.Breaking Down the PAH Cost Burden

EP: 6.A New Era in PAH Treatment?

EP: 7.Clinical Evidence for Emerging PAH Therapies

EP: 8.Integrating New PAH Therapies into Clinical Practice

EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension

EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH

EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

EP: 13.Optimizing PAH Care Delivery for Better Outcomes

EP: 14.Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following questions:

• What are the direct medical costs and indirect socioeconomic costs associated with managing pulmonary arterial hypertension (PAH), including hospitalizations, outpatient care, and impacts on patient productivity and quality of life?
• How does the overall burden of PAH, in terms of clinical outcomes and resource utilization, vary across different patient populations and health care settings? Are there any disparities that clinicians and payers should be more aware of?